Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Recommendations

Info

286 Applying Pharmacogenomics in Therapeutics40. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing beforeanticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J GenIntern Med. 2009;24:656–664.41. Garcia DA. Warfarin and pharmacogenomic testing: The case for restraint. ClinPharmacol Ther. 2008;84:303–305.42. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policymodel to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.PharmacoEconomics. 2010;28:61–74.43. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogeneticinformation in warfarin dosing for patients with nonvalvular atrial fibrillation.Ann Intern Med. 2009;150:73–83.44. Centers for Medicare and Medicaid Services. Decision memo for pharmacogenomictesting to predict warfarin response (CAG-00400N). Available from: http://www.cms.hhs.gov/site-search/serach-results.html?q=warfarin (accessed April 23, 2014).45. Xie HG, Zhang YD. Pharmacogenomics and personalized medicine of the antiplateletdrugs. In: Barh D, Dhawan D, Ganguly NK, eds. Omics for Personalized Medicine.Springer India, New Delhi, India, 2013, pp. 469–506.46. Lala A, Berger JS, Sharma G, Hochman JS, Scott Braithwaite R, Ladapo JA. Genetictesting in patients with acute coronary syndrome undergoing percutaneous coronaryintervention: A cost-effectiveness analysis. J Thromb Haemost. 2013;11:81–91.47. Thompson CA. Clopidogrel poor metabolizers may need alternative to standardregimen. Am J Health-Syst Pharm. 2010;67:779–780.48. Panattoni L, Brown PM, Te Ao B, Webster M, Gladding P. The cost effectiveness ofgenetic testing for CYP2C19 variants to guide thienopyridine treatment in patientswith acute coronary syndromes: A New Zealand evaluation. Pharmacoeconomics.2012;30:1067–1084.49. Xie HG, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drugdisposition and response. In: Cho AK, Blaschke TF, Insel PA, Loh HH, eds. AnnualReview of Pharmacology and Toxicology, Vol. 41. Annual Reviews, Palo Alto, CA,2001, pp. 815–850.50. Wu AC, Fuhlbrigge AL. Economic evaluation of pharmacogenetic tests. ClinPharmacol Ther. 2008;84:272–274.51. Hicks DG, Tubbs RR. Assessment of HER2 status in breast cancer by fluorescencein situ hybridization: A technical review with interpretive guidelines. Hum Pathol.2005;36:250–261.52. Valachis A, Nearchou A, Polyzos NP, Lind P. Cardiotoxicity in breast cancer patientstreated with dual HER2 blockade. Int J Cancer. 2013;133:2245–2252.
5’3’5’3’ 5’3’ 5’3’3’5’3’5’3’5’3’5’5’3’5’3’5’5’3’DNA templatePrimerdNTPDNA polymeraseA alleleG alleleDenaturation(a)5’ATA5’3’5’C 5’G3’C5’(b)GTaqMan probeAT 5’ATAnnealingElongationCyclingGenotypeA/A A/G G/GSample A Partitioning AmplificationSample B5’3’(c)5’(d)FIGURE 2.1 Illustration of polymerase chain reaction (PCR)–related methods. (a) A PCRcycle generally includes denaturation, annealing, and elongation steps. (b) A representativedesign for a tetra-primer set, which integrates allele-specific nucleotides into the 3′-endsof primers. (c) A modified graph showing the mechanism of SNP genotyping by TaqManassay (Life Technologies) using allele-specific fluorophore-conjugated probes. The perfectlymatched TaqMan probe that anneals to the template will be degraded by DNA polymeraseand release the fluorescence (yellow), while the fluorophore (blue) of the mismatched TaqManprobe that does not anneal will remain quenched. (d) Strategy of digital PCR to quantitativelyestimate the starting DNA templates. Sample A has fewer starting templates, whichare shown in fewer positive digital PCR reactions. For sample B, more starting templates areshown in more positive digital PCR reactions.
Page 1:
ApplyingPharmacogenomicsin Therapeu
Page 5 and 6:
ApplyingPharmacogenomicsin Therapeu
Page 7:
DedicationWe dedicate this book to
Page 10 and 11:
viiiContentsChapter 10 Pharmacogeno
Page 13 and 14:
EditorsXiaodong Feng, PhD, PharmD,
Page 15 and 16:
ContributorsWeiguo Chen, PhDDepartm
Page 17 and 18:
1Concepts inPharmacogenomics andPer
Page 19 and 20:
Concepts in Pharmacogenomics and Pe
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
2Principles ofPharmacogeneticBiotec
Page 51 and 52:
Principles of Pharmacogenetic Biote
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65:
Page 68 and 69:
52 Applying Pharmacogenomics in The
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 91 and 92:
4 ApplyingPharmacogenomicsin Drug D
Page 93 and 94:
Applying Pharmacogenomics in Drug D
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
5 Pharmacogenomicsand Laboratory Me
Page 113 and 114:
Pharmacogenomics and Laboratory Med
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157:
Page 160 and 161:
144 Applying Pharmacogenomics in Th
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 217 and 218:
8Clinical Applicationsof Pharmacoge
Page 219 and 220:
Pharmacogenomics of CNS Disorder Tr
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
9 ApplyingPharmacogenomicsin the Th
Page 239 and 240:
Applying Pharmacogenomics in the Th
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252: Applying Pharmacogenomics in the Th
Page 259 and 260: 10Pharmacogenomics andAlternative M
Page 261 and 262: Pharmacogenomics and Alternative Me
Page 287 and 288: 11 PharmacoeconogenomicsA Good Marr
Page 289 and 290: Pharmacoeconomics of Pharmacogenomi
Page 301: Pharmacoeconomics of Pharmacogenomi
Page 305 and 306: 1 2 3 4 5Vysis LSI BCR/ABL + 9q34 t
Page 307: BIOMEDICAL SCIENCEApplying Pharmaco
show all

Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Create successful ePaper yourself

Delete template?

Save as template?